Cite
HARVARD Citation
Genge, A. et al. (2023). Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. Muscle & nerve. 67 (2), pp. 124-129. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Genge, A. et al. (2023). Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. Muscle & nerve. 67 (2), pp. 124-129. [Online].